Priority Date: 25.11.11 (SG 20110008800)

NATURAL-KILLER/T-CELL LYMPHOMA (NKTCL) SUSCEPTIBILITY PREDICTION, DIAGNOSIS AND THERAPY

  • Application ID: EP12799341
  • Status: PATENT GRANTED

Applicant

Attorneys

operating since 1887
Headquarter in London and 16 offices
active in Legal Services, IP Consulting, and Matchmaking and Trading
operating since 1887
Headquarter in London and 16 offices
active in Legal Services, IP Consulting, and Matchmaking and Trading

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING) is specialized in the combination A61 and C12. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Sperling Fischer & Heyner, Zacco Denmark A/S, Lederer Keller Patentanwälte Partnerschaft mbB and 171 others are specialized in all of these IPC classes. For a similar patent, they might be a good choice.

Timeline

  • 25.11.2011 - Priority Date (SG 20110008800)
  • 30.05.2013 - Publication A2 (WO2013077814)
  • 01.10.2014 - Publication A2 (EP2782562)
  • 21.12.2016 - Publication B1 (EP2782562)

IPC Classification